[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2302486A1 - Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53 - Google Patents

Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53 Download PDF

Info

Publication number
CA2302486A1
CA2302486A1 CA002302486A CA2302486A CA2302486A1 CA 2302486 A1 CA2302486 A1 CA 2302486A1 CA 002302486 A CA002302486 A CA 002302486A CA 2302486 A CA2302486 A CA 2302486A CA 2302486 A1 CA2302486 A1 CA 2302486A1
Authority
CA
Canada
Prior art keywords
wildtype
risk
p53arg
polymorphic forms
p53pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002302486A
Other languages
French (fr)
Other versions
CA2302486C (en
Inventor
Greg Matlashewski
Lawrence Banks
Alan Storey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Cancer Research Horizons Ltd
INTERNATIONAL CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY(ICGEB)
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002214461A external-priority patent/CA2214461A1/en
Application filed by Individual filed Critical Individual
Priority to CA002302486A priority Critical patent/CA2302486C/en
Publication of CA2302486A1 publication Critical patent/CA2302486A1/en
Application granted granted Critical
Publication of CA2302486C publication Critical patent/CA2302486C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a screening method to identify individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53; which comprises the steps of: a) obtaining a biological sample from said patients; and b) determining the presence of p53pro or p53arg wildtype alleles in said sample; wherein the allele pattern of patients selected from the group consisting of p53pro/p53pro, p53arg/p53arg and p53pro/p53arg are indicative of a risk factor for developing disease associated with different polymorphic forms of wildtype p53. Notably, individuals who are p53arg/arg are at greater risk of developing pathologies associated with human papillomavirus infections, including cervical cancer.
CA002302486A 1997-09-02 1998-08-31 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53 Expired - Fee Related CA2302486C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002302486A CA2302486C (en) 1997-09-02 1998-08-31 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002214461A CA2214461A1 (en) 1997-09-02 1997-09-02 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
CA2,214,461 1997-09-02
PCT/CA1998/000828 WO1999011817A1 (en) 1997-09-02 1998-08-31 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
CA002302486A CA2302486C (en) 1997-09-02 1998-08-31 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53

Publications (2)

Publication Number Publication Date
CA2302486A1 true CA2302486A1 (en) 1999-03-11
CA2302486C CA2302486C (en) 2009-07-14

Family

ID=25679585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002302486A Expired - Fee Related CA2302486C (en) 1997-09-02 1998-08-31 Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53

Country Status (1)

Country Link
CA (1) CA2302486C (en)

Also Published As

Publication number Publication date
CA2302486C (en) 2009-07-14

Similar Documents

Publication Publication Date Title
AU8969098A (en) Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
EP1246114A3 (en) Methods for genomic analysis
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
EP2319936A3 (en) Yeast screens for agents affecting protein folding
WO1998027227B1 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
EP2793189A3 (en) Assessment of lesions in an image
CA2188933A1 (en) Apolipoprotein E Polymorphism and Treatment of Alzheimer's Disease
EP1073368A4 (en) Aspiration screening process for assessing post surgery patient's risk for pneumonia
AU6416198A (en) Diagnostic means useful for predictive assessment of human hepatocellular carc inoma disease (hcc), as well as diagnostic methods using the same
WO2001000661A3 (en) Carnitine carrier related protein-1
EP1408333A3 (en) Diagnosis and treatment of Alzheimer's disease
CA2443929A1 (en) Detection and quantification of prion isoforms in neurodegenerative diseases using mass spectrometry
WO2002074911A3 (en) Identification of gene expression alterations underlying the aging process in mammals
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
CA2302486A1 (en) Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
AU4261901A (en) Quantitative analysis of biological images
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO1999042619A3 (en) Association of the serotonin transport (htt) gene with cardiovascular disease and longevity
WO2001079560A3 (en) Medicine response assay in respiratory disease
AU2003276727A8 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
WO2005037204A3 (en) Ntrk1 genetic markers associated with age of onset of alzheimer's disease
AU2890297A (en) The use of a genetic modification in the gene for human G protein beta3 subunit for the diagnosis of diseases
WO2004113566A3 (en) Disease related protein network
Morey ACS updates guidelines on screening for colorectal cancer.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150831